{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T01:18:45Z","timestamp":1794100725366,"version":"4.8.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T00:00:00Z","timestamp":1562025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T00:00:00Z","timestamp":1562025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["P30MH092177"],"award-info":[{"award-number":["P30MH092177"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["R01MH110360"],"award-info":[{"award-number":["R01MH110360"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["P30MH062261"],"award-info":[{"award-number":["P30MH062261"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["P01DA037830"],"award-info":[{"award-number":["P01DA037830"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA042706"],"award-info":[{"award-number":["R01DA042706"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS036126"],"award-info":[{"award-number":["R01NS036126"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS034239"],"award-info":[{"award-number":["R01NS034239"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Elimination of HIV-1 requires clearance and removal of integrated proviral DNA from infected cells and tissues. Here, sequential long-acting slow-effective release antiviral therapy (LASER ART) and CRISPR-Cas9 demonstrate viral clearance in latent infectious reservoirs in HIV-1 infected humanized mice. HIV-1 subgenomic DNA fragments, spanning the long terminal repeats and the Gag gene, are excised in vivo, resulting in elimination of integrated proviral DNA; virus is not detected in blood, lymphoid tissue, bone marrow and brain by nested and digital-droplet PCR as well as RNAscope tests. No CRISPR-Cas9 mediated off-target effects are detected. Adoptive transfer of human immunocytes from dual treated, virus-free animals to uninfected humanized mice fails to produce infectious progeny virus. In contrast, HIV-1 is readily detected following sole LASER ART or CRISPR-Cas9 treatment. These data provide proof-of-concept that permanent viral elimination is possible.<\/jats:p>","DOI":"10.1038\/s41467-019-10366-y","type":"journal-article","created":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T12:02:39Z","timestamp":1562068959000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":275,"title":["Sequential LASER ART and CRISPR Treatments Eliminate HIV-1 in a Subset of Infected Humanized Mice"],"prefix":"10.1038","volume":"10","author":[{"given":"Prasanta K.","family":"Dash","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafal","family":"Kaminski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramona","family":"Bella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saumi","family":"Mathews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taha M.","family":"Ahooyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Mancuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahsan","family":"Sariyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Ferrante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Donadoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jake A.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brady","family":"Sillman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Hilaire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Banoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monalisha","family":"Elango","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagsen","family":"Gautam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Lee","family":"Mosley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larisa Y.","family":"Poluektova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JoEllyn","family":"McMillan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya N.","family":"Bade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santhi","family":"Gorantla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilker K.","family":"Sariyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tricia H.","family":"Burdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won-Bin","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohreh","family":"Amini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benson","family":"Edagwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamel","family":"Khalili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard E.","family":"Gendelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,2]]},"reference":[{"key":"10366_CR1","doi-asserted-by":"publisher","first-page":"13193","DOI":"10.1073\/pnas.94.24.13193","volume":"94","author":"TW Chun","year":"1997","unstructured":"Chun, T. W. et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl Acad. Sci. USA 94, 13193\u201313197 (1997).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"10366_CR2","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nature16933","volume":"530","author":"R Lorenzo-Redondo","year":"2016","unstructured":"Lorenzo-Redondo, R. et al. Persistent HIV-1 replication maintains the tissue reservoir during therapy. Nature 530, 51\u201356 (2016).","journal-title":"Nature"},{"key":"10366_CR3","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/nm.4108","volume":"22","author":"SG Deeks","year":"2016","unstructured":"Deeks, S. G. et al. International AIDS Society global scientific strategy: towards an HIV cure 2016. Nat. Med. 22, 839\u2013850 (2016).","journal-title":"Nat. Med."},{"key":"10366_CR4","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1056\/NEJMoa0802905","volume":"360","author":"G Hutter","year":"2009","unstructured":"Hutter, G. et al. Long-term control of HIV by CCR5 Delta32\/Delta32 stem-cell transplantation. New Engl. J. Med. 360, 692\u2013698 (2009).","journal-title":"New Engl. J. Med."},{"key":"10366_CR5","doi-asserted-by":"crossref","unstructured":"Gupta, R. K. et al. HIV-1 remission following CCR5Delta32\/Delta32 haematopoietic stem-cell transplantation. Nature 568, 244\u2013248 (2019).","DOI":"10.1038\/s41586-019-1027-4"},{"key":"10366_CR6","first-page":"343","volume":"30","author":"JZ Li","year":"2016","unstructured":"Li, J. Z. et al. The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption. AIDS 30, 343\u2013353 (2016).","journal-title":"AIDS"},{"key":"10366_CR7","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1146\/annurev-med-011514-023043","volume":"67","author":"AR Martin","year":"2016","unstructured":"Martin, A. R. & Siliciano, R. F. Progress toward HIV eradication: case reports, current efforts, and the challenges associated with cure. Annu. Rev. Med. 67, 215\u2013228 (2016).","journal-title":"Annu. Rev. Med."},{"key":"10366_CR8","doi-asserted-by":"publisher","first-page":"e1003211","DOI":"10.1371\/journal.ppat.1003211","volume":"9","author":"A Saez-Cirion","year":"2013","unstructured":"Saez-Cirion, A. et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog. 9, e1003211 (2013).","journal-title":"PLoS Pathog."},{"key":"10366_CR9","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1172\/JCI86047","volume":"126","author":"JD Siliciano","year":"2016","unstructured":"Siliciano, J. D. & Siliciano, R. F. Recent developments in the effort to cure HIV infection: going beyond N\u2009=\u20091. J. Clin. Investig. 126, 409\u2013414 (2016).","journal-title":"J. Clin. Investig."},{"key":"10366_CR10","first-page":"6096134","volume":"2017","author":"W Xu","year":"2017","unstructured":"Xu, W. et al. Advancements in developing strategies for sterilizing and functional HIV cures. BioMed. Res. Int. 2017, 6096134 (2017).","journal-title":"BioMed. Res. Int."},{"key":"10366_CR11","doi-asserted-by":"publisher","first-page":"16538","DOI":"10.1073\/pnas.1315295110","volume":"110","author":"JA Horwitz","year":"2013","unstructured":"Horwitz, J. A. et al. HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proc. Natl Acad. Sci. USA 110, 16538\u201316543 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"10366_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-02885-x","volume":"9","author":"B Sillman","year":"2018","unstructured":"Sillman, B. et al. Creation of a long-acting nanoformulated dolutegravir. Nat. Commun. 9, 443 (2018).","journal-title":"Nat. Commun."},{"key":"10366_CR13","doi-asserted-by":"publisher","first-page":"e75","DOI":"10.1097\/QAI.0000000000001170","volume":"74","author":"D Guo","year":"2017","unstructured":"Guo, D. et al. Creation of a Long-Acting Nanoformulated 2\u2019,3\u2019-Dideoxy-3\u2019-Thiacytidine. J. Acquir Immune Defic. Syndr. 74, e75\u2013e83 (2017).","journal-title":"J. Acquir Immune Defic. Syndr."},{"key":"10366_CR14","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.2217\/nnm-2016-0164","volume":"11","author":"D Singh","year":"2016","unstructured":"Singh, D. et al. Development and characterization of a long-acting nanoformulated abacavir prodrug. Nanomedicine 11, 1913\u20131927 (2016).","journal-title":"Nanomedicine"},{"key":"10366_CR15","doi-asserted-by":"publisher","first-page":"4186","DOI":"10.2174\/0929867321666140826114135","volume":"21","author":"BJ Edagwa","year":"2014","unstructured":"Edagwa, B. J., Zhou, T., McMillan, J. M., Liu, X. M. & Gendelman, H. E. Development of HIV reservoir targeted long acting nanoformulated antiretroviral therapies. Curr. Med. Chem. 21, 4186\u20134198 (2014).","journal-title":"Curr. Med. Chem."},{"key":"10366_CR16","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1080\/17425247.2017.1288212","volume":"14","author":"B Edagwa","year":"2017","unstructured":"Edagwa, B., McMillan, J., Sillman, B. & Gendelman, H. E. Long-acting slow effective release antiretroviral therapy. Expert Opin. Drug Deliv. 14, 1281\u20131291 (2017).","journal-title":"Expert Opin. Drug Deliv."},{"key":"10366_CR17","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1097\/QAD.0b013e328357f5ad","volume":"26","author":"PK Dash","year":"2012","unstructured":"Dash, P. K. et al. Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice. AIDS 26, 2135\u20132144 (2012).","journal-title":"AIDS"},{"key":"10366_CR18","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.biomaterials.2018.09.018","volume":"185","author":"BM Ottemann","year":"2018","unstructured":"Ottemann, B. M. et al. Bioimaging predictors of rilpivirine biodistribution and antiretroviral activities. Biomaterials 185, 174\u2013193 (2018).","journal-title":"Biomaterials"},{"key":"10366_CR19","doi-asserted-by":"publisher","first-page":"11461","DOI":"10.1073\/pnas.1405186111","volume":"111","author":"W Hu","year":"2014","unstructured":"Hu, W. et al. RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. Proc. Natl Acad. Sci. USA 111, 11461\u201311466 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"10366_CR20","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/gt.2016.41","volume":"23","author":"R Kaminski","year":"2016","unstructured":"Kaminski, R. et al. Excision of HIV-1 DNA by gene editing: a proof-of-concept in vivo study. Gene Ther. 23, 690\u2013695 (2016).","journal-title":"Gene Ther."},{"key":"10366_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/srep22555","volume":"6","author":"R Kaminski","year":"2016","unstructured":"Kaminski, R. et al. Elimination of HIV-1 genomes from human t-lymphoid cells by CRISPR\/Cas9 gene editing. Sci. Rep. 6, 22555 (2016).","journal-title":"Sci. Rep."},{"key":"10366_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/srep31527","volume":"6","author":"R Kaminski","year":"2016","unstructured":"Kaminski, R. et al. Negative feedback regulation of HIV-1 by gene editing strategy. Sci. Rep. 6, 31527 (2016).","journal-title":"Sci. Rep."},{"key":"10366_CR23","doi-asserted-by":"publisher","first-page":"e1005953","DOI":"10.1371\/journal.ppat.1005953","volume":"12","author":"MK White","year":"2016","unstructured":"White, M. K., Hu, W. & Khalili, K. Gene editing approaches against viral infections and strategy to prevent occurrence of viral escape. PLoS Pathog. 12, e1005953 (2016).","journal-title":"PLoS Pathog."},{"key":"10366_CR24","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1016\/j.ymthe.2017.03.012","volume":"25","author":"C Yin","year":"2017","unstructured":"Yin, C. et al. In vivo excision of HIV-1 Provirus by saCas9 and Multiplex single-guide RNAs in animal models. Mol. Ther. 25, 1168\u20131186 (2017).","journal-title":"Mol. Ther."},{"key":"10366_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2005.01.003","volume":"107","author":"SA Hunsucker","year":"2005","unstructured":"Hunsucker, S. A., Mitchell, B. S. & Spychala, J. The 5\u2019-nucleotidases as regulators of nucleotide and drug metabolism. Pharmacol. Ther. 107, 1\u201330 (2005).","journal-title":"Pharmacol. Ther."},{"key":"10366_CR26","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2165\/00003088-200847060-00001","volume":"47","author":"GJ Yuen","year":"2008","unstructured":"Yuen, G. J., Weller, S. & Pakes, G. E. A review of the pharmacokinetics of abacavir. Clin. Pharmacokinet. 47, 351\u2013371 (2008).","journal-title":"Clin. Pharmacokinet."},{"key":"10366_CR27","doi-asserted-by":"publisher","first-page":"88","DOI":"10.2174\/1574884711666160329192333","volume":"11","author":"H Singh","year":"2016","unstructured":"Singh, H., Kaur, M., Kakkar, A. K. & Kumar, H. The promise of dolutegravir: a novel second generation integrase strand transfer inhibitor. Curr. Clin. Pharmacol. 11, 88\u201394 (2016).","journal-title":"Curr. Clin. Pharmacol."},{"key":"10366_CR28","first-page":"35","volume":"3","author":"N Ford","year":"2011","unstructured":"Ford, N., Lee, J., Andrieux-Meyer, I. & Calmy, A. Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settings. HIV\/AIDS 3, 35\u201344 (2011).","journal-title":"HIV\/AIDS"},{"key":"10366_CR29","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.biomaterials.2017.10.023","volume":"151","author":"T Zhou","year":"2018","unstructured":"Zhou, T. et al. Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles. Biomaterials 151, 53\u201365 (2018).","journal-title":"Biomaterials"},{"key":"10366_CR30","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1128\/JVI.02010-06","volume":"81","author":"S Gorantla","year":"2007","unstructured":"Gorantla, S. et al. Human immunodeficiency virus type 1 pathobiology studied in humanized BALB\/c-Rag2-\/-gammac-\/- mice. J. Virol. 81, 2700\u20132712 (2007).","journal-title":"J. Virol."},{"key":"10366_CR31","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.2353\/ajpath.2010.100536","volume":"177","author":"S Gorantla","year":"2010","unstructured":"Gorantla, S. et al. Links between progressive HIV-1 infection of humanized mice and viral neuropathogenesis. Am. J. Pathol. 177, 2938\u20132949 (2010).","journal-title":"Am. J. Pathol."},{"key":"10366_CR32","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1523\/JNEUROSCI.5473-10.2011","volume":"31","author":"PK Dash","year":"2011","unstructured":"Dash, P. K. et al. Loss of neuronal integrity during progressive HIV-1 infection of humanized mice. J. Neurosci. 31, 3148\u20133157 (2011).","journal-title":"J. Neurosci."},{"key":"10366_CR33","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/1750-1326-9-58","volume":"9","author":"MD Boska","year":"2014","unstructured":"Boska, M. D. et al. Associations between brain microstructures, metabolites, and cognitive deficits during chronic HIV-1 infection of humanized mice. Mol. Neurodegener. 9, 58 (2014).","journal-title":"Mol. Neurodegener."},{"key":"10366_CR34","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1007\/s11481-011-9335-y","volume":"7","author":"S Gorantla","year":"2012","unstructured":"Gorantla, S., Gendelman, H. E. & Poluektova, L. Y. Can humanized mice reflect the complex pathobiology of HIV-associated neurocognitive disorders? J. NeuroImmune Pharmacol. 7, 352\u2013362 (2012).","journal-title":"J. NeuroImmune Pharmacol."},{"issue":"3","key":"10366_CR35","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.tins.2011.12.006","volume":"35","author":"Santhi Gorantla","year":"2012","unstructured":"Gorantla, S., Poluektova, L., Gendelman, H. E. Rodent models for HIV-associated neurocognitive disorders. Trends Neurosci, 35, 197\u2013208 (2012).","journal-title":"Trends in Neurosciences"},{"key":"10366_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/srep23513","volume":"6","author":"M Arainga","year":"2016","unstructured":"Arainga, M., Su, H., Poluektova, L. Y., Gorantla, S. & Gendelman, H. E. HIV-1 cellular and tissue replication patterns in infected humanized mice. Sci. Rep. 6, 23513 (2016).","journal-title":"Sci. Rep."},{"key":"10366_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-017-0344-7","volume":"14","author":"M Arainga","year":"2017","unstructured":"Arainga, M. et al. A mature macrophage is a principal HIV-1 cellular reservoir in humanized mice after treatment with long acting antiretroviral therapy. Retrovirology 14, 17 (2017).","journal-title":"Retrovirology"},{"key":"10366_CR38","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.antiviral.2015.05.009","volume":"120","author":"P Puligujja","year":"2015","unstructured":"Puligujja, P. et al. Pharmacodynamics of folic acid receptor targeted antiretroviral nanotherapy in HIV-1-infected humanized mice. Antivir. Res 120, 85\u201388 (2015).","journal-title":"Antivir. Res"},{"key":"10366_CR39","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1172\/JCI90025","volume":"127","author":"DP Gnanadhas","year":"2017","unstructured":"Gnanadhas, D. P. et al. Autophagy facilitates macrophage depots of sustained-release nanoformulated antiretroviral drugs. J. Clin. Invest 127, 857\u2013873 (2017).","journal-title":"J. Clin. Invest"},{"key":"10366_CR40","volume-title":"Humanized Mice for HIV Research","year":"2014","unstructured":"Poluektova, L. Y., Garcia, J. V., Koyanagi, Y., Manz, M. G., Tager, A. M. (eds). Humanized Mice for HIV Research (Springer, New York, 2014)."},{"key":"10366_CR41","first-page":"109","volume-title":"AIDS Res Hum Retroviruses","author":"R Akkina","year":"2016","unstructured":"Akkina, R. et al. Improvements and limitations of humanized mouse models for hiv research: NIH\/NIAID \u201cMeet the Experts\u201d 2015 Workshop Summary. AIDS Res Hum Retroviruses 32, 109\u2013119 (2016)."},{"key":"10366_CR42","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1146\/annurev-virology-101416-041703","volume":"4","author":"MD Marsden","year":"2017","unstructured":"Marsden, M. D. & Zack, J. A. Humanized mouse models for human immunodeficiency virus infection. Annu Rev. Virol. 4, 393\u2013412 (2017).","journal-title":"Annu Rev. Virol."},{"issue":"1","key":"10366_CR43","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s11481-018-9785-6","volume":"14","author":"Jonathan Herskovitz","year":"2018","unstructured":"Herskovitz, J., Gendelman, H. E. HIV and the macrophage: from cell reservoirs to drug delivery to viral eradication. J Neuroimmune Pharmacol. 14, 52\u201367 (2018).","journal-title":"Journal of Neuroimmune Pharmacology"},{"key":"10366_CR44","volume-title":"Pharmacokinetic Testing of a First Generation Cabotegravir Prodrug in Rhesus Macaques","author":"J McMillan","year":"2018","unstructured":"McMillan, J. et al. Antiretroviral drug metabolism in humanized PXR-CAR-CYP3A-NOG mice. J. Pharmacol. Exp. Ther. 365, 272\u2013280 (2018)."},{"key":"10366_CR45","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1182\/blood-2006-03-012534","volume":"108","author":"H Dou","year":"2006","unstructured":"Dou, H. et al. Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. Blood 108, 2827\u20132835 (2006).","journal-title":"Blood"},{"key":"10366_CR46","doi-asserted-by":"publisher","first-page":"661","DOI":"10.4049\/jimmunol.0900274","volume":"183","author":"H Dou","year":"2009","unstructured":"Dou, H. et al. Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS. J. Immunol. 183, 661\u2013669 (2009).","journal-title":"J. Immunol."},{"key":"10366_CR47","doi-asserted-by":"crossref","unstructured":"Edagwa, B., McMillan, J., Sillman, B. & Gendelman, H. E. Long-acting slow effective release antiretroviral therapy. Expert Opin. Drug Deliv. 14, 1281\u20131291 (2017).","DOI":"10.1080\/17425247.2017.1288212"},{"key":"10366_CR48","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.omtn.2018.05.021","volume":"12","author":"R Bella","year":"2018","unstructured":"Bella, R. et al. Removal of HIV DNA by CRISPR from patient blood engrafts in humanized mice. Mol. Ther. Nucleic Acids 12, 275\u2013282 (2018).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10366_CR49","doi-asserted-by":"publisher","first-page":"871","DOI":"10.2217\/nnm-2017-0381","volume":"13","author":"T Zhou","year":"2018","unstructured":"Zhou, T. et al. Optimizing the preparation and stability of decorated antiretroviral drug nanocrystals. Nanomed. 13, 871\u2013885 (2018).","journal-title":"Nanomed."},{"key":"10366_CR50","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.nano.2015.09.009","volume":"12","author":"G Zhang","year":"2016","unstructured":"Zhang, G. et al. The mixed lineage kinase-3 inhibitor URMC-099 improves therapeutic outcomes for long-acting antiretroviral therapy. Nanomedicine 12, 109\u2013122 (2016).","journal-title":"Nanomedicine"},{"key":"10366_CR51","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.biomaterials.2014.11.012","volume":"41","author":"P Puligujja","year":"2015","unstructured":"Puligujja, P. et al. Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations. Biomaterials 41, 141\u2013150 (2015).","journal-title":"Biomaterials"},{"key":"10366_CR52","doi-asserted-by":"publisher","first-page":"9504","DOI":"10.1128\/JVI.01557-14","volume":"88","author":"D Guo","year":"2014","unstructured":"Guo, D. et al. Endosomal trafficking of nanoformulated antiretroviral therapy facilitates drug particle carriage and HIV clearance. J. Virol. 88, 9504\u20139513 (2014).","journal-title":"J. Virol."},{"key":"10366_CR53","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.jconrel.2010.11.019","volume":"150","author":"AS Nowacek","year":"2011","unstructured":"Nowacek, A. S. et al. Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages. J. Control Release 150, 204\u2013211 (2011).","journal-title":"J. Control Release"},{"key":"10366_CR54","doi-asserted-by":"crossref","unstructured":"Balkundi, S. et al. Methods development for blood borne macrophage carriage of nanoformulated antiretroviral drugs. J. Vis. Exp.\n                            2460,\u00a0PMC3052269 (2010).","DOI":"10.3791\/2460"},{"key":"10366_CR55","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1007\/s11481-010-9198-7","volume":"5","author":"AS Nowacek","year":"2010","unstructured":"Nowacek, A. S. et al. Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroAIDS therapeutics. J. Neuroimmune Pharm. 5, 592\u2013601 (2010).","journal-title":"J. Neuroimmune Pharm."},{"key":"10366_CR56","doi-asserted-by":"publisher","first-page":"256","DOI":"10.7150\/thno.22764","volume":"8","author":"BD Kevadiya","year":"2018","unstructured":"Kevadiya, B. D. et al. Multimodal theranostic nanoformulations permit magnetic resonance bioimaging of antiretroviral drug particle tissue-cell biodistribution. Theranostics 8, 256\u2013276 (2018).","journal-title":"Theranostics"},{"key":"10366_CR57","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1086\/506364","volume":"194","author":"JM Jacobson","year":"2006","unstructured":"Jacobson, J. M. et al. Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068. J. Infect. Dis. 194, 623\u2013632 (2006).","journal-title":"J. Infect. Dis."},{"key":"10366_CR58","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1126\/science.aag1276","volume":"354","author":"SN Byrareddy","year":"2016","unstructured":"Byrareddy, S. N. et al. Sustained virologic control in SIV\u2009+\u2009macaques after antiretroviral and alpha4beta7 antibody therapy. Sci. (New Y., NY) 354, 197\u2013202 (2016).","journal-title":"Sci. (New Y., NY)"},{"key":"10366_CR59","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/nm.4319","volume":"23","author":"JB Honeycutt","year":"2017","unstructured":"Honeycutt, J. B. et al. HIV persistence in tissue macrophages of humanized myeloid-only mice during antiretroviral therapy. Nat. Med. 23, 638\u2013643 (2017).","journal-title":"Nat. Med."},{"key":"10366_CR60","doi-asserted-by":"publisher","first-page":"10074","DOI":"10.1128\/JVI.74.21.10074-10080.2000","volume":"74","author":"U O\u2019Doherty","year":"2000","unstructured":"O\u2019Doherty, U., Swiggard, W. J. & Malim, M. H. Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J. Virol. 74, 10074\u201310080 (2000).","journal-title":"J. Virol."},{"key":"10366_CR61","doi-asserted-by":"publisher","first-page":"S270","DOI":"10.1086\/655651","volume":"202","author":"MS Cohen","year":"2010","unstructured":"Cohen, M. S., Gay, C. L., Busch, M. P. & Hecht, F. M. The detection of acute HIV infection. J. Infect. Dis. 202, S270\u2013S277 (2010).","journal-title":"J. Infect. Dis."},{"key":"10366_CR62","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.virol.2007.06.001","volume":"368","author":"LM Agosto","year":"2007","unstructured":"Agosto, L. M. et al. HIV-1 integrates into resting CD4\u2009+\u2009T cells even at low inoculums as demonstrated with an improved assay for HIV-1 integration. Virology 368, 60\u201372 (2007).","journal-title":"Virology"},{"key":"10366_CR63","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1128\/JCM.00055-08","volume":"46","author":"AO Pasternak","year":"2008","unstructured":"Pasternak, A. O. et al. Highly sensitive methods based on seminested real-time reverse transcription-PCR for quantitation of human immunodeficiency virus type 1 unspliced and multiply spliced RNA and proviral DNA. J. Clin. Microbiol. 46, 2206\u20132211 (2008).","journal-title":"J. Clin. Microbiol."},{"key":"10366_CR64","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.ymeth.2009.01.002","volume":"47","author":"MK Liszewski","year":"2009","unstructured":"Liszewski, M. K., Yu, J. J. & O\u2019Doherty, U. Detecting HIV-1 integration by repetitive-sampling Alu-gag PCR. Methods 47, 254\u2013260 (2009).","journal-title":"Methods"},{"key":"10366_CR65","doi-asserted-by":"publisher","first-page":"68","DOI":"10.20411\/pai.v1i1.100","volume":"1","author":"C Deleage","year":"2016","unstructured":"Deleage, C. et al. Defining HIV and SIV reservoirs in lymphoid tissues. Pathog. Immunity 1, 68\u2013106 (2016).","journal-title":"Pathog. Immunity"},{"key":"10366_CR66","doi-asserted-by":"publisher","first-page":"10056","DOI":"10.1128\/JVI.01046-14","volume":"88","author":"MJ Buzon","year":"2014","unstructured":"Buzon, M. J. et al. Long-term antiretroviral treatment initiated at primary HIV-1 infection affects the size, composition, and decay kinetics of the reservoir of HIV-1-infected CD4 T cells. J. Virol. 88, 10056\u201310065 (2014).","journal-title":"J. Virol."},{"key":"10366_CR67","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/nm.3445","volume":"20","author":"MJ Buzon","year":"2014","unstructured":"Buzon, M. J. et al. HIV-1 persistence in CD4\u2009+\u2009T cells with stem cell-like properties. Nat. Med. 20, 139\u2013142 (2014).","journal-title":"Nat. Med."},{"key":"10366_CR68","doi-asserted-by":"publisher","first-page":"e1003398","DOI":"10.1371\/journal.ppat.1003398","volume":"9","author":"GM Laird","year":"2013","unstructured":"Laird, G. M. et al. Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay. PLoS Pathog. 9, e1003398 (2013).","journal-title":"PLoS Pathog."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-10366-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-10366-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-10366-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T18:59:58Z","timestamp":1671217198000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-10366-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,2]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["10366"],"URL":"https:\/\/doi.org\/10.1038\/s41467-019-10366-y","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.736111078.793563720","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,2]]},"assertion":[{"value":"15 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.K. and RK are named inventors on patents that cover the viral gene editing technology that is the subject of this article. HEG and BE are named inventors on patents that cover the medicinal and polymer chemistry technologies that were also employed in this manuscript. In addition to the foregoing interests, KK is a co-founder, board member, scientific advisor, and holds equity in Excision Biotherapeutics, a biotech start-up that has licensed the viral gene editing technology from Temple University for commercial development and clinical trials. H.E.G. is the founder of Brain First, a second independent biotech start-up and is the operative head of the Nebraska Nanomedicine Production Plant, a good manufacturing program facility that was responsible for synthesizing the long-acting slow effective release antiretroviral therapies used in the accompanying report. The authors declare that this work was produced solely by the authors and that no other individuals or entities influenced any aspects of the work including, but not limited to, the study conception and design; data acquisition, analysis and interpretation; and writing of the manuscript. No other entities provided funds for the work. The authors further declare that they have received no financial compensation from any other third parties for any aspects of the published work. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2753"}}